1. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger- Ellison syndrome: A 13-year prospective study 
Basil I. Hirschowitz, Julie Simmons, Jean Mohnen 
Clinical Gastroenterology and Hepatology 
Volume 3, Issue 1, Pages (January 2005)
DOI: /S (04)
Copyright © 2005 American Gastroenterological Association Terms and Conditions

2. Figure 1
(A) Symptoms before treatment and as reported at 1050 return visits (3–6-month intervals) for an average 15.7 visits per patient during treatment. No patients were asymptomatic before treatment. (B) Lesions and complications before and during a median period of 6.25 years of therapy. All paired columns are significantly different (P <.001). Note: During treatment, 4 patients listed under both ulcer and esophagitis had both lesions (ulcer + esophagitis).
Clinical Gastroenterology and Hepatology 2005 3, 39-48DOI: ( /S (04) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

3. Figure 2
The percent distribution of intact and post-antrectomy patients, respectively, with no relapse, mild relapses, and more complicated or serious relapses.
Clinical Gastroenterology and Hepatology 2005 3, 39-48DOI: ( /S (04) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

4. Figure 3
Acid and pepsin output (basal and peak) (A) during relapse of ulcer and/or esophagitis in 20 patients, as well as (B) during remission in the same patients, and (C) in the 47 patients who never experienced relapse.
Clinical Gastroenterology and Hepatology 2005 3, 39-48DOI: ( /S (04) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

5. Figure 4
(A) Relapses of esophagitis and ulcer: all episodes in 14 intact patients showing BAO and month of recurrence. The means ± 2 SEs for the 44 patients who did not relapse are shown by the solid and dashed lines. (B) As in panel A, but for 6 antrectomized ZES patients.
Clinical Gastroenterology and Hepatology 2005 3, 39-48DOI: ( /S (04) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

6. Figure 5
LESP and BAO in 14 patients who had relapse of esophagitis (•) compared to 32 who did not (○). For reference, the vertical lines denote mean BAO (±3 SEs) of the nonrelapsers. The threshold LESP (16 mm Hg)27 is indicated by the dashed horizontal line. EST, esophagitis.
Clinical Gastroenterology and Hepatology 2005 3, 39-48DOI: ( /S (04) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions